Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3090
Fax+1 617-632-4448
Dr. Hanna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2016
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2011 - 2014
Mass General Brigham/Massachusetts Eye and Ear/Harvard Medical SchoolInternship, Otolaryngology - Head and Neck Surgery, 2010 - 2011
Georgetown University School of MedicineClass of 2010
Certifications & Licensure
MA State Medical License 2012 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia Start of enrollment: 2018 Dec 05
- A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma Start of enrollment: 2019 Aug 05
- Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas Start of enrollment: 2020 Dec 24
- Join now to see all
Publications & Presentations
PubMed
- Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.Jia Luo, Justin A Bishop, Steven G DuBois, Glenn J Hanna, Lynette M Sholl
Nature Reviews. Clinical Oncology. 2025-04-01 - Current Progress and Future Directions of Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Narrative Review.Edward S Sim, Hoang C B Nguyen, Glenn J Hanna, Ravindra Uppaluri
JAMA Otolaryngology-- Head & Neck Surgery. 2025-03-06 - Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma.Glenn J Hanna, L B Oakley, R Shi, A ONeill, K Y Shin
Clinical Cancer Research. 2025-02-17
Journal Articles
- Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaGlenn J Hanna, Nicole Chau, Jochen Lorch, Robert I Haddad, JAMA Oncology
- Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid TumorsJeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature
- CIC‐NUTM1 Fusion: A Case Which Expands the Spectrum of NUT‐Rearranged Epithelioid MalignanciesGlenn J Hanna, Christopher A French, Genes, Chromosomes and Cancer
Authored Content
- Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020
Press Mentions
“Eye-Opening” Data Raise Concerns About Off-Label Immunotherapy Use in Head and Neck CancerMarch 24th, 2025- Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 DataNovember 20th, 2024
- Higher Cancer Risk with Heavy Cannabis Use – US StudyAugust 21st, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
